Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Offer Wholly Unconditional

17 Jan 2020 07:00

RNS Number : 0961A
Open Orphan PLC
17 January 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION

 

17 January 2020

Recommended All Equity Offer

for

HVIVO PLC ("HVIVO")

to merge with

OPEN ORPHAN PLC ("OPEN ORPHAN")

 

 Offer Wholly Unconditional

Introduction

On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the "Offer"). Under the terms of the Offer, hVIVO Shareholders will be entitled to receive 2.47 New Open Orphan Shares for every one hVIVO Share. The Offer represents a value of approximately 15.56 pence per hVIVO Share and a premium of 33.8 per cent. based upon the hVIVO Closing Price on 6 December 2019, being the last practicable date prior to announcement of the Offer, valuing hVIVO at approximately £12.96 million.

On 31 December 2019, Open Orphan announced that the Offer had been declared unconditional as to acceptances and on 14 January 2020 announced that it had received acceptances in respect of 77,348,100 hVIVO Shares, representing approximately 92.5 per cent. of the issued ordinary share capital of hVIVO.

Offer Wholly Unconditional

Open Orphan announces that it has decided, in accordance with the Offer Document, to waive the outstanding conditions under the Offer. Accordingly, there are no further conditions to be satisfied and the Offer is now unconditional in all respects.

Admission of the Enlarged Share Capital

Application has been made for the admission of the Consideration Shares and the Existing Ordinary Shares, being 445,622,374 Ordinary Shares to trading on AIM and Euronext Growth, which is expected to become effective and dealings commence at 8.00 a.m. on 20 January 2020.

Compulsory acquisition

Open Orphan intends to shortly exercise its rights pursuant to the provisions of sections 974-991 of the Companies Act to compulsorily acquire the remaining hVIVO Shares. The compulsory acquisition will be settled on the same terms as the Offer and hVIVO Shareholders will be entitled to receive 2.47 Open Orphan Shares for every 1 hVIVO Share.

In exercising such rights in respect of hVIVO Shares held by hVIVO Shareholders in, or with a registered address in, a Restricted Jurisdiction, Open Orphan may elect to arrange for such hVIVO Shares to be sold on behalf of the relevant hVIVO Shareholder and the proceeds (less the costs and expenses of such sale) remitted to such hVIVO Shareholder.

Enquiries:

 

Open Orphan plc

Cathal Friel, Chief Executive Officer

 

+353 (0)1 644 0007

Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Ben Cryer

 

+44 (0)20 7614 5900

JE Davy (Euronext Adviser and Joint Broker)

Anthony Farrell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OUPUNUARRRUAAUR
Date   Source Headline
28th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSAppointment of Non Executive Director
13th Sep 20167:00 amRNSDirectorate Change
24th Aug 20167:00 amRNSNotice of Results
3rd Aug 20167:00 amRNSContract wins
30th Jun 201612:18 pmRNSResult of AGM
30th Jun 20167:00 amRNSAGM Statement
20th Jun 20164:24 pmRNSShareholder notification
10th Jun 201611:05 amRNSPosting of Annual Report and Notice of AGM
10th May 20167:00 amRNSFinal Results
24th Mar 20167:00 amRNSYear End Update
18th Jan 20168:00 amRNSEnterprise Securities Market Notice
13th Jan 20167:00 amRNSESM Schedule 1 update
13th Jan 20167:00 amRNSESM Appendix to Schedule 1 update
12th Jan 20167:00 amRNSContracts worth EUR 3.4m signed with US Biotech
8th Jan 20162:03 pmRNSHolding(s) in Company
8th Jan 20167:01 amRNSTrading update
8th Jan 20167:00 amRNSDirectorate Change
11th Dec 20157:00 amRNSChange of Adviser
11th Dec 20157:00 amRNSESM Pre-Admission Announcement
11th Dec 20157:00 amRNSAppendix to Schedule 1 announcement
3rd Nov 20157:00 amRNSGrant of Share Option & Total Voting Rights
23rd Oct 20157:00 amRNSContract for over EUR1m with French Biotech
19th Oct 20157:00 amRNSAppointment of Director
19th Oct 20157:00 amRNSCompletion of the Acquisition of Kinesis Pharma BV
9th Oct 201511:38 amRNSResult of General Meeting & Update on Acquisition
22nd Sep 20157:01 amRNSHalf Yearly Report
22nd Sep 20157:00 amRNSProposed acquisition & Placing
24th Aug 20152:00 pmRNSAppointment of Co-Broker
21st Aug 20157:00 amRNSNotice of Results
13th Aug 20157:00 amRNSTrading update
30th Jun 201511:39 amRNSResult of AGM
30th Jun 20157:00 amRNSAGM Statement
15th Jun 20157:00 amRNSAppointment of Chief Financial Officer
10th Jun 20153:46 pmRNSEUR 2m contract with leading European biotech
28th May 201510:14 amRNSPosting of Annual Report & Notice of AGM
22nd May 20157:00 amRNSFinal Results
20th May 20153:29 pmRNSHolding(s) in Company
20th May 20157:00 amRNSNew services from Innovenn
12th May 20157:01 amRNSDirectorate Change
8th Apr 20159:06 amRNSHolding(s) in Company
8th Apr 20159:05 amRNSHolding(s) in Company
7th Apr 20152:39 pmRNSHolding(s) in Company
7th Apr 201511:17 amRNSHolding(s) in Company
2nd Apr 20152:00 pmRNSInvestor teach-in
2nd Apr 20157:00 amRNSInnoVenn expands products and first sales in US
1st Apr 201512:14 pmRNSResult of General Meeting
30th Mar 20157:00 amRNSContracts for EUR4.1m with US Biotech client
13th Mar 20154:45 pmRNSPlacing to raise £2 million
6th Mar 20157:00 amRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.